, Volume 47, Issue 1, pp 7–11 | Cite as

Vancomycin-resistant enterococci (VRE): a reason to isolate?

  • Maria J. G. T. Vehreschild
  • Miriam Haverkamp
  • Lena M. Biehl
  • Sebastian Lemmen
  • Gerd FätkenheuerEmail author


In recent years, an increase in invasive VRE infections has been reported worldwide, including Germany. The most common gene encoding resistance to glycopeptides is VanA, but predominant VanB clones are emerging. Although neither the incidence rates nor the exact routes of nosocomial transmission of VRE are well established, screening and strict infection control measures, e.g. single room contact isolation, use of personal protective clothing by hospital staff and intensified surface disinfection for colonized individuals, are implemented in many hospitals. At the same time, the impact of VRE infection on mortality remains unclear, with current evidence being weak and contradictory. In this short review, we aim to give an overview on the current basis of evidence on the clinical effectiveness of infection control measures intended to prevent transmission of VRE and to put these findings into a larger perspective that takes further factors, e.g. VRE-associated mortality and impact on patient care, into account.


Enterococci Vancomycin Vancomycin-resistant Isolation Infection control Screening 


Compliance with ethical standards

Conflict of interest

LMB has received lecture honoraria from Astellas and Merck/MSD, and travel grants from 3M and Gilead. MJGTV is a consultant to: Alb-Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Berlin Chemie, DaVolterra, MaaT Pharma and Merck/MSD; has served at the speakers’ bureau of: Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer; received research funding from: 3M, Astellas Pharma, DaVolterra, Gilead Sciences, MaaT Pharma, Merck/MSD, Morphochem, Organobalance, Seres Therapeutics.


  1. 1.
    ECDC. Surveillance atlas of infectious diseases. 2018. Accessed 16 Aug 2018.Google Scholar
  2. 2.
    Remschmidt C, et al. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany—10 years of surveillance. Antimicrob Resist Infect Control. 2018;7:54.CrossRefPubMedGoogle Scholar
  3. 3.
    Werner G, et al. Enterococcus faecium strains from bloodstream infections of German hospital patients revealed a preferred prevalence of ST117 and an increasing number of vanB-type VRE between 2011 and 2017. In: European Congress of Microbiology and Infectious Diseases, Madrid; 2018.Google Scholar
  4. 4.
    McDermott H, et al. Vancomycin-resistant enterococci (VRE) in the intensive care unit in a nonoutbreak setting: identification of potential reservoirs and epidemiological associations between patient and environmental VRE. Infect Control Hosp Epidemiol. 2018;39:40–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosko AE, et al. Vancomycin-resistant enterococci infection: not just for the transplanted. Leuk Lymphoma. 2014;55:1320–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen CH, et al. Clinical and microbiological characteristics of vancomycin-resistant Enterococcus faecium bloodstream infection in Central Taiwan. Medicine (Baltimore). 2017;96:e9000.CrossRefGoogle Scholar
  7. 7.
    Webb BJ, et al. Prediction of bloodstream infection due to vancomycin-resistant enterococcus in patients undergoing leukemia induction or hematopoietic stem-cell transplantation. Clin Infect Dis. 2017;64:1753–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Taur Y, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14.CrossRefPubMedGoogle Scholar
  9. 9.
    DiazGranados CA, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Cho SY, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis. 2013;13:504.CrossRefPubMedGoogle Scholar
  11. 11.
    Mahony AA, et al. Vancomycin-resistant Enterococcus faecium sequence type 796—rapid international dissemination of a new epidemic clone. Antimicrob Resist Infect Control. 2018;7:44.CrossRefPubMedGoogle Scholar
  12. 12.
    Moulin E, et al. Vancomycine-resistant enterococci (VRE): a new reality in our hospitals. Rev Med Suisse. 2018;14:791–4.PubMedGoogle Scholar
  13. 13.
    Wagenvoort JH, et al. Environmental survival of vancomycin-resistant Enterococcus faecium. J Hosp Infect. 2011;77:282–3.CrossRefPubMedGoogle Scholar
  14. 14.
    van Hal SJ, et al. Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation. J Antimicrob Chemother. 2018;73:1487–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Yeh KM, et al. Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units. Microb Drug Resist. 2004;10:177–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Amberpet R, et al. Risk factors for intestinal colonization with vancomycin resistant enterococci’ a prospective study in a level III pediatric intensive care unit. J Lab Physicians. 2018;10:89–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Liss BJ, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Gedik H, et al. Vancomycin-resistant enterococci colonization and bacteremia in patients with hematological malignancies. J Infect Dev Ctries. 2014;8:1113–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Biehl LM, Stemler HP, Gillis J, Peter M, Dörfel S, Vogel W, Kern WV, Gölz H, Bertz H, Rohde H, Klupp EM, Schafhausen P, Salmanton-García J, Ertel J, Zweigner J, Seifert H, Vehreschild MJGT, Impact of single room contact precautions on hospital-acquisition and transmission of vancomycin-resistant enterococci in a high-risk setting: preliminary results from the CONTROL study||Oral #O0177 in 28th ECCMID, Madrid; 2018.Google Scholar
  20. 20.
    Kamboj M, et al. The changing epidemiology of vancomycin-resistant enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16:1576–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Ornstein MC, et al. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. Leuk Lymphoma. 2015;56:2536–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Tavadze M, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:1310–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Vydra J, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:764–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Ford CD, et al. Frequency, risk factors, and outcomes of vancomycin-resistant enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Ford CD, et al. The clinical impact of vancomycin-resistant enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation. Transpl Infect Dis. 2015;17:688–94.CrossRefPubMedGoogle Scholar
  26. 26.
    Satlin MJ, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55:2858–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Hefazi M, et al. Vancomycin-resistant enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016;18:913–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Fournier S, Brun-Buisson C, Jarlier V. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control. 2012;1:9.CrossRefPubMedGoogle Scholar
  29. 29.
    Huang SS, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255–65.CrossRefPubMedGoogle Scholar
  30. 30.
    Martin EM, et al. Elimination of routine contact precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: a retrospective quasi-experimental study. Infect Control Hosp Epidemiol. 2016;37:1323–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Bardossy AC, et al. Evaluation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. Am J Infect Control. 2017;45:1369–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Bearman G, et al. Impact of discontinuing contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: an interrupted time series analysis. Infect Control Hosp Epidemiol. 2018;39:676–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Marra AR, et al. Discontinuing contact precautions for multidrug-resistant organisms: a systematic literature review and meta-analysis. Am J Infect Control. 2018;46:333–40.CrossRefPubMedGoogle Scholar
  34. 34.
    Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis. 2010;14:S3–S5.CrossRefPubMedGoogle Scholar
  35. 35.
    Pidot SJ, et al. Increasing tolerance of hospital Enterococcus faecium to handwash alcohols. Sci Transl Med, 2018;10:eaar6115. Scholar
  36. 36.
    Frakking FNJ, et al. Recommendations for the successful control of a large outbreak of vancomycin-resistant Enterococcus faecium in a non-endemic hospital setting. J Hosp Infect. 2018;21:S0195–6701(18)30109–9. Scholar
  37. 37.
    Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA. 2003;290:1899–905.CrossRefPubMedGoogle Scholar
  38. 38.
    Morgan DJ, et al. Adverse outcomes associated with contact precautions: a review of the literature. Am J Infect Control. 2009;37:85–93.CrossRefPubMedGoogle Scholar
  39. 39.
    Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect. 2010;76:97–102.CrossRefPubMedGoogle Scholar
  40. 40.
    Martin EM, et al. Noninfectious hospital adverse events decline after elimination of contact precautions for MRSA and VRE. Infect Control Hosp Epidemiol. 2018;39:788–96.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Maria J. G. T. Vehreschild
    • 1
    • 2
  • Miriam Haverkamp
    • 3
  • Lena M. Biehl
    • 1
    • 2
  • Sebastian Lemmen
    • 3
  • Gerd Fätkenheuer
    • 1
    • 2
    Email author
  1. 1.Department I of Internal MedicineUniversity Hospital of CologneCologneGermany
  2. 2.Deutsches Zentrum für Infektionsforschung (DZIF)Standort Bonn-CologneGermany
  3. 3.Zentralbereich für Krankenhaushygiene und InfektiologieUniklinik AachenAachenGermany

Personalised recommendations